
|Videos|March 14, 2017
Access to High Cost Drugs Remains a Challenge in Specialty
Author(s)Lauren Santye, Assistant Editor
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Advertisement
Paul LeVine, vice president of Analytic Services at Trial Card, discusses potential ways to overcome the hurdle of limited access to high cost specialty drugs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
2
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
3
FDA Expands Approval of Sotatercept-Csrk for Pulmonary Arterial Hypertension
4
Study Shows Growing Confidence in Cell and Gene Therapies Across the Care Continuum
5














































































































































































































